Sugi Predict

Sugi Predict / Compounds / SCHEMBL55833

SCHEMBL55833

SCHEMBL55833

COC(=O)C(CC(C)C)NC(=O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 2/20 0.60
▸ CTSK P43235 2/20 0.60
▸ CTSB P07858 1/20 0.60
▸ CTSS P25774 1/20 0.60
▸ CAPN1 P07384 1/20 0.52
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ CA7 P43166 1/20 0.51
▸ PSEN1 P49768 2/20 0.49
▸ PSEN2 P49810 2/20 0.49
▸ APH1B Q8WW43 2/20 0.49
▸ NCSTN Q92542 2/20 0.49
▸ APH1A Q96BI3 2/20 0.49
▸ PSENEN Q9NZ42 2/20 0.49
▸ TAS1R3 Q7RTX0 1/20 0.48
▸ TAS1R1 Q7RTX1 1/20 0.48
▸ AAK1 Q2M2I8 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ POLB P06746 2/20 0.46
▸ BIRC2 Q13490 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL56907 1.00 CTSL (0.60) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL55832 1.00 CTSL (0.60) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL1026997 0.94 CTSL (0.62) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL1176795 0.94 CTSL (0.62) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL1026994 0.94 CTSL (0.62) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL21675512 0.91 CTSK (0.61) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL23080082 0.90 CTSL (0.54) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL16668218 0.90 CTSL (0.54) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL6897731 0.90 CTSK (0.60) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL12588811 0.89 CTSL (0.53) CTSLCTSKCTSBCTSSCAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116670143-A Modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-08-29 — — CN disclosed
WO-2022076625-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
CN-113924297-A N-1 branched alkyl substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods 3M创新有限公司 2022-01-11 — — CN disclosed
CN-112969698-A Chemical compound 葛兰素史密斯克莱知识产权发展有限公司 2021-06-15 — — CN disclosed
US-10364269-B2 Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof LAURUS LABS LIMITED (IN) 2019-07-30 — — US disclosed
CN-108137446-A Anthracene -9,10- dione dioxime compound prodrug and application thereof 贝塔卡特药业有限公司 2018-06-08 — — CN disclosed
EP-2943475-B1 PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE GILEAD PHARMASSET LLC (US) 2017-10-25 — — EP disclosed
US-20140045943-A1 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof NAUREX, INC. (US) 2014-02-13 — — US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 — — US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 — — EP disclosed
CN-1341592-A Proteinase inhibitor SMITHKLINE BEECHEM CORP (US) 2002-03-27 — — CN disclosed
CN-1341593-A Proteinase inhibitor SMITHKLINE BEECHEM CORP (US) 2002-03-27 — — CN disclosed
CN-1341590-A Proteinase inhibitor SMITHKLINE BEECHEM CORP (US) 2002-03-27 — — CN disclosed
CN-1304392-A Process for producing carboxylic acid derivative and condensing agent comprising quaternary ammonium salt TOKUYAMA CORP (JP) 2001-07-18 — — CN disclosed
CN-1207095-A Protease inhibitors SMITHKLINE BEECHAM CORP (US) 1999-02-03 — — CN disclosed
EP-0212903-B1 POLYPEPTIDE DERIVATIVES CONTAINING 5-AMINO-2,5-DISUBSTITUTED-4-HYDROXYPENTANOIC ACID RESIDUES PFIZER INC. (US) 1992-12-30 — — EP disclosed
US-4992562-A Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues PFIZER INC. (US) 1991-02-12 — — US disclosed
US-4948913-A Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues PFIZER INC. (US) 1990-08-14 — — US disclosed
US-4729985-A Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues PFIZER INC. (US) 1988-03-08 — — US disclosed
EP-0212903-A2 Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues PFIZER INC. (US) 1987-03-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10364269-B2 Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof SF3B5, PRCP, GBA1 CTSL 81/4885CTSK 252/4885CTSB 217/4885
US-20140045943-A1 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof GLS, HGFAC, AADAC CTSL 426/4885CTSK 251/4885CTSB 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.